Actimed reacquires global S-oxprenolol rights as $126 million Faraday licensing deal ends

The rights reversion gives Actimed full control of the muscle-wasting candidate across all indications, with amyotrophic lateral sclerosis remaining its primary development focus.

Actimed Therapeutics has reacquired from Faraday Pharmaceuticals the worldwide development, manufacturing and commercialisation rights to S-oxprenolol (ACM-002), ending a 2021 licensing agreement that included up to $126.2 million in potential milestone payments.

The transaction consolidates the asset under Actimed's control and gives the company greater flexibility to develop the programme in amyotrophic lateral sclerosis (ALS) and evaluate other muscle-wasting indications.

Field	Content
Alert Type	Deal
Companies	Actimed Therapeutics; Faraday Pharmaceuticals
Deal Type	Rights reacquisition / termination of licensing agreement
Asset or Company	S-oxprenolol (ACM-002)
Therapy Area(s)	Neurology; Muscle-wasting disorders; Cachexia
Technology or Modality	Anabolic-catabolic transforming agent (ACTA)
Deal Value	Financial terms of the rights reversion were not disclosed. Under the original 2021 agreement, Actimed received $550,000 in upfront cash and equity, was eligible for a $2.7 million near-term milestone and up to $123.5 million in total potential milestone payments, plus royalties. These contingent payments should not be treated as consideration received under the new transaction. (Actimed Therapeutics)
Development Stage	Preclinical / pre-clinical development for S-oxprenolol; Actimed plans to initiate clinical development in ALS following completion of chemistry, manufacturing and controls (CMC) work. (Fierce Biotech)
Geography	Global
What Happened	On 6 August 2026, Actimed announced that it had negotiated the return of all rights to S-oxprenolol from Faraday Pharmaceuticals, giving Actimed worldwide development, manufacturing and commercialisation control. Under the original 2021 agreement, Faraday had obtained global rights to develop and commercialise S-oxprenolol for cancer cachexia and other indications outside ALS, while Actimed retained ALS rights. The reversion therefore reunifies the asset's global rights under Actimed. (Fierce Biotech)
Why It Matters	Reacquiring the rights allows Actimed to determine S-oxprenolol's development and partnering strategy across indications rather than retaining control only in ALS. The company continues to identify ALS-associated muscle wasting and cachexia as its primary focus for the asset, which has received FDA Orphan Drug Designation for ALS, while the wider rights could enable exploration of other muscle-wasting disorders. (Fierce Biotech)
Supporting Context	Actimed licensed most S-oxprenolol rights to Faraday in 2021 while retaining global ALS rights. S-oxprenolol is an ACTA that has generated preclinical evidence in models of muscle wasting, but its potential clinical benefit remains to be established in human trials. (Actimed Therapeutics)
Strategic Rationale	Full ownership gives Actimed control over future development, manufacturing, commercialisation and potential partnering of S-oxprenolol worldwide, removing the indication-based division of rights established under the Faraday agreement. (Fierce Biotech)
Key Takeaway	Reacquiring S-oxprenolol reunifies worldwide rights under Actimed and gives the company control over the asset's future development across ALS and other potential muscle-wasting indications.
What to Watch	Completion of CMC work and Actimed's planned initiation of an ALS clinical development programme, together with any decision to advance S-oxprenolol in additional muscle-wasting indications or seek new partners. (Fierce Biotech)
Primary Source	Actimed Therapeutics announcement, 6 August 2026
Relevant Date	6 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com